Neurofit Participates in BioUSA... Supporting Dementia Drug Development with Imaging CRO Services

Neurofit, a specialized company in brain disease imaging artificial intelligence (AI) solutions, announced on the 30th that it will participate in the 2024 BIO International Convention (BIO USA) held in San Diego, California, USA, from the 3rd to the 6th of next month (local time).

Bin Jun-gil, CEO of Neurofit. Photo by Jinhyung Kang aymsdream@

At this BIO USA, Neurofit plans to focus on showcasing its imaging contract research organization (CRO) services that can be utilized in clinical trials for Alzheimer's disease drug development. Neurofit's imaging CRO services analyze medical images collected during clinical trials such as positron emission tomography (PET) and magnetic resonance imaging (MRI) using Neurofit Aqua, a brain neurodegeneration imaging analysis software that has obtained premarket clearance (510k) from the U.S. Food and Drug Administration (FDA), and Neurofit Scale PET, a PET image quantitative analysis software, to identify biomarkers.

This service provides consistent analysis results, playing a crucial role in ensuring image data quality and regulatory compliance, while also offering high efficiency in terms of time and cost. It can be utilized throughout the entire clinical process?from identifying patient groups for clinical trials to efficacy analysis and side effect monitoring?thereby increasing the success rate of new drug development for pharmaceutical and biotech companies.

Neurofit is currently supporting the identification of clinical trial patient groups by participating in and collaborating on the global Phase 3 clinical trial of 'AR1001,' a multi-mechanism oral Alzheimer's disease treatment developed by Aribio.

Bin Jungil, CEO of Neurofit, stated, “Many pharmaceutical companies are actively advancing new drug development through partnerships with AI specialized companies to overcome the limitations of traditional drug development, and this trend is expected to expand further.” He added, “Neurofit’s imaging CRO services can contribute to improving clinical success rates and operational efficiency, providing significant opportunities for global pharmaceutical companies developing Alzheimer's disease treatments.” He also said, “We have scheduled meetings with various global pharmaceutical companies at this BIO USA and will do our best to establish meaningful partnerships.”

This content was produced with the assistance of AI translation services.